(Q37855884)

24 August 2017

1 reference

title

Therapeutic potential of boron-containing compounds (English)

1 reference

24 August 2017

0 references

Stephen J Baker

1

1 reference

24 August 2017

Charles Z Ding

2

1 reference

24 August 2017

Tsutomu Akama

3

1 reference

24 August 2017

Yong-Kang Zhang

4

1 reference

24 August 2017

Vincent Hernandez

5

1 reference

24 August 2017

Yi Xia

6

1 reference

24 August 2017

1 October 2009

1 reference

Future Medicinal Chemistry

24 August 2017

1 reference

24 August 2017

1

1 reference

24 August 2017

7

1 reference

24 August 2017

1275-1288

1 reference

Daily boron intake from the American diet

24 August 2017

1 reference

Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites

21 January 2018

1 reference

Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).

21 January 2018

1 reference

Boronic acid compounds as potential pharmaceutical agents

21 January 2018

1 reference

Boron therapeutics on the horizon

21 January 2018

1 reference

Boron neutron capture therapy of cancer: current status and future prospects

21 January 2018

1 reference

Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues

21 January 2018

1 reference

A diazaborine derivative inhibits lipopolysaccharide biosynthesis.

21 January 2018

1 reference

A mechanism of drug action revealed by structural studies of enoyl reductase

21 January 2018

1 reference

Mechanism of action of diazaborines.

21 January 2018

1 reference

Syntheses and evaluation of benzodiazaborine compounds against M. tuberculosis H37Rv in vitro

21 January 2018

1 reference

A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase

21 January 2018

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.

21 January 2018

1 reference

P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease

21 January 2018

1 reference

Potent inhibitors of HCV-NS3 protease derived from boronic acids

21 January 2018

1 reference

The crisis in antibiotic resistance

21 January 2018

1 reference

Beta-lactamase-mediated resistance and opportunities for its control

21 January 2018

1 reference

A functional classification scheme for beta-lactamases and its correlation with molecular structure

21 January 2018

1 reference

Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments

21 January 2018

1 reference

Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitors

21 January 2018

1 reference

Structure, function, and inhibition along the reaction coordinate of CTX-M beta-lactamases

21 January 2018

1 reference

Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis

21 January 2018

1 reference

In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate

21 January 2018

1 reference

An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site

21 January 2018

1 reference

Cytochemistry of membrane proteases

21 January 2018

1 reference

21 January 2018

1 reference

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).

21 January 2018

1 reference

Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function

21 January 2018

1 reference

Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides

21 January 2018

1 reference

Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety

21 January 2018

1 reference

Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.

21 January 2018

1 reference

The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects

21 January 2018

1 reference

Molecular diversity of cyclic AMP signalling

21 January 2018

1 reference

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

21 January 2018

1 reference

Phosphodiesterase inhibitors: new opportunities for the treatment of asthma

21 January 2018

1 reference

PDE4-regulated cAMP degradation controls the assembly of integrin-dependent actin adhesion structures and REF52 cell migration

21 January 2018

1 reference

Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis

21 January 2018

1 reference

Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases

21 January 2018

1 reference

Recent Developments in β-Lactamases and Inhibitors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/FMC.09.71

1 reference

24 August 2017

1 reference